Subject: Revlon Gets FDA Clearance For New Drug, Factorate
Date: Published: 2/16/84 25 lines
Source:  Wall Street Journal.  Copyright Dow Jones Inc. 

   Revlon Gets FDA Clearance
   For New Drug, Factorate

   NEW YORK -- Revlon Inc. said it received Food and Drug
Administration clearance to sell its new drug, heat-treated
Factorate, for bleeding associated with hemophilia A. 
   Factorate concentrates are derived from human plasma and
manufactured by a Revlon subsidiary, Armour Pharmaceutical
Co., Tarrytown, N. Y. Revlon said it plans to begin selling
Factorate within the next several weeks.
   Revlon said the heat-treated Factorate is intended to
reduce the possibility of the transmission of viruses,
including hepatitis and acquired immune deficiency syndrome,
or AIDS, a risk frequently encountered with coagulation
drugs.
   Revlon makes cosmetics, fragrances and pharmaceuticals.

[This article is made available here by Dow Jones Co. for the 
personal and non-commercial use of callers to this bbs, in the 
hope that it will be of some help to those who are suffering 
from the disease and others who are seeking to help them.]